Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

Publisher： Karger

E-ISSN： 1423-0232|79|3-4|174-180

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.3-4, 2011-02, pp. : 174-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

By Maniadakis Nikos   Fragoulakis Vasilios   Pectasides Dimitrios   Fountzilas George  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 797-805

Informa Healthcare

Access to resources Recommend Favorite

Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4145-4153

John Wiley & Sons Inc

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 233-239

Karger

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

By  

Oncology, Vol. 71, Iss. 1-2, 2007-04 ,pp. : 40-48

Karger

Access to resources Recommend Favorite